PLoS ONE (Jan 2020)

Evaluation of metronomic chemotherapy response using diffusion and dynamic contrast-enhanced MRI.

  • Mehran Baboli,
  • Kerryanne V Winters,
  • Melanie Freed,
  • Jin Zhang,
  • Sungheon Gene Kim

DOI
https://doi.org/10.1371/journal.pone.0241916
Journal volume & issue
Vol. 15, no. 11
p. e0241916

Abstract

Read online

PurposeTo investigate the feasibility of using diffusion MRI (dMRI) and dynamic contrast-enhanced (DCE) MRI to evaluate the treatment response of metronomic chemotherapy (MCT) in the 4T1 mammary tumor model of locally advanced breast cancer.MethodsTwelve Balb/c mice with metastatic breast cancer were divided into treated and untreated (control) groups. The treated group (n = 6) received five treatments of anti-metabolite agent 5-Fluorouracil (5FU) in the span of two weeks. dMRI and DCE-MRI were acquired for both treated and control groups before and after MCT. Immunohistochemically staining and measurements were performed after the post-MRI measurements for comparison.ResultsThe control mice had significantly (pConclusiondMRI and DCE-MRI can be used as potential biomarkers for assessing the treatment response of MCT. The MRI and pathology observations suggested that in addition to the cytotoxic effect of cell kills, the MCT with a cytotoxic drug, 5FU, induced changes in the tumor vasculature similar to the anti-angiogenic effect.